NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $54.53 +1.81 (+3.43 %) (As of 12/12/2018 08:41 AM ET)Previous Close$52.72Today's Range$53.16 - $55.8052-Week Range$50.96 - $99.82Volume930,679 shsAverage Volume476,654 shsMarket Capitalization$3.09 billionP/E Ratio-8.08Dividend YieldN/ABeta2.18 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts. Receive AGIO News and Ratings via Email Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGIO Previous Symbol CUSIPN/A Webwww.agios.com Phone617-649-8600 Debt Debt-to-Equity RatioN/A Current Ratio8.21 Quick Ratio8.20 Price-To-Earnings Trailing P/E Ratio-8.08 Forward P/E Ratio-8.91 P/E GrowthN/A Sales & Book Value Annual Sales$43.01 million Price / Sales73.76 Cash FlowN/A Price / Cash FlowN/A Book Value$7.69 per share Price / Book7.09 Profitability EPS (Most Recent Fiscal Year)($6.75) Net Income$-314,670,000.00 Net Margins-461.78% Return on Equity-48.51% Return on Assets-38.25% Miscellaneous Employees382 Outstanding Shares58,180,000Market Cap$3.09 billion OptionableOptionable Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions What is Agios Pharmaceuticals' stock symbol? Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO." How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals Inc (NASDAQ:AGIO) issued its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the Zacks' consensus estimate of ($1.62) by $0.01. The biopharmaceutical company had revenue of $15.20 million for the quarter, compared to the consensus estimate of $22.72 million. Agios Pharmaceuticals had a negative return on equity of 48.51% and a negative net margin of 461.78%. Agios Pharmaceuticals's quarterly revenue was up 33.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.59) earnings per share. View Agios Pharmaceuticals' Earnings History. When is Agios Pharmaceuticals' next earnings date? Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Agios Pharmaceuticals. What price target have analysts set for AGIO? 13 brokers have issued twelve-month target prices for Agios Pharmaceuticals' stock. Their forecasts range from $80.00 to $125.00. On average, they anticipate Agios Pharmaceuticals' share price to reach $97.50 in the next year. This suggests a possible upside of 78.8% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals. What is the consensus analysts' recommendation for Agios Pharmaceuticals? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals. What are Wall Street analysts saying about Agios Pharmaceuticals stock? Here are some recent quotes from research analysts about Agios Pharmaceuticals stock: 1. Canaccord Genuity analysts commented, "We maintain a favorable view on Fouse as the CEO given her expensive experience at Laboratories, holding various senior roles focusing on corporate strategies, finance, and operations. We believe Fouse will help maintain AGIO’s heading in launching the approved products and developing the pipeline." (9/5/2018) 2. Needham & Company LLC analysts commented, "BeiGene announced the pricing of its Hong Kong initial public offering of 65,600,000 ordinary shares. Based on the assumed exchange rate, the public offering, priced at $13.76 (HK$108) per share or $178.9 per American Depositary Share (ADS) is expected to raise ~$903M (HK$7.08bn)." (8/2/2018) 3. According to Zacks Investment Research, "Agios received an FDA approval of Idhifa (enasidenib) in August for treatment of AML, which was a huge boost, given the immense commercial potential in the target market. We are also optimistic about its collaboration with Celgene as it provides Agios with regular funds. The company’s progress with the pipeline candidates, AG-120 and AG-881, has been quite impressive too. In December, the company submitted a new drug application to the FDA for AG-120 for treatment of AML. Shares of the company have outperformed the industry in the last one year. However, Agios depends heavily on partner Celgene for revenues as Idhifa is only in the early stages of launch. Also, the decision to discontinue the development of AG-519 was disappointing. Stiff competition is another matter of concern for the company." (1/16/2018) Has Agios Pharmaceuticals been receiving favorable news coverage? Press coverage about AGIO stock has been trending positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Agios Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. Who are some of Agios Pharmaceuticals' key competitors? Some companies that are related to Agios Pharmaceuticals include Genmab A/S (GNMSF), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Beigene (BGNE), Perrigo (PRGO), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX) and GALAPAGOS NV/S (GLPG). Who are Agios Pharmaceuticals' key executives? Agios Pharmaceuticals' management team includes the folowing people: Dr. David P. Schenkein, CEO, Pres & Director (Age 61)Dr. Lewis Clayton Cantley, Co-Founder & Member of Scientific Advisory Board (Age 69)Mr. Andrew Hirsch, Chief Financial Officer (Age 47)Dr. Scott A. Biller Ph.D., Chief Scientific Officer (Age 62)Dr. Christopher J. Bowden, Chief Medical Officer (Age 57) Who are Agios Pharmaceuticals' major shareholders? Agios Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.95%), Vanguard Group Inc. (7.31%), BlackRock Inc. (5.65%), Capital International Investors (5.32%), First Trust Advisors LP (2.00%) and Baillie Gifford & Co. (1.15%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Celgene European Investment Co, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, John Maraganore, Kaye I Foster-Cheek, Lewis Clayton Jr Cantley, Robert Nelsen, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals. Which major investors are selling Agios Pharmaceuticals stock? AGIO stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Deutsche Bank AG, Artal Group S.A., Marshall Wace North America L.P., Morgan Stanley, Pictet Asset Management Ltd., Capital International Ltd. CA and Bellevue Group AG. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, David P Schenkein, John Maraganore, Kaye I Foster-Cheek, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals. Which major investors are buying Agios Pharmaceuticals stock? AGIO stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Capital International Investors, Vanguard Group Inc., FMR LLC, Cannell Peter B & Co. Inc., Allianz Asset Management GmbH, Baillie Gifford & Co. and Dimensional Fund Advisors LP. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Celgene European Investment Co, Corp /De/ Celgene and David Scadden. View Insider Buying and Selling for Agios Pharmaceuticals. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Agios Pharmaceuticals' stock price today? One share of AGIO stock can currently be purchased for approximately $54.53. How big of a company is Agios Pharmaceuticals? Agios Pharmaceuticals has a market capitalization of $3.09 billion and generates $43.01 million in revenue each year. The biopharmaceutical company earns $-314,670,000.00 in net income (profit) each year or ($6.75) on an earnings per share basis. Agios Pharmaceuticals employs 382 workers across the globe. What is Agios Pharmaceuticals' official website? The official website for Agios Pharmaceuticals is http://www.agios.com. How can I contact Agios Pharmaceuticals? Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected] MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 328 (Vote Outperform)Underperform Votes: 288 (Vote Underperform)Total Votes: 616MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: How is an ETF different from a mutual fund?